Trade Tracker: Joe Terranova buys Interactive Brokers and McKesson, sells CVS
Joe Terranova, Senior Managing Director for Virtus Investment Partners, joins CNBC's "Halftime Report" to detail his latest portfolio moves.
McKesson (MCK) and Visa (V) Are 2 Dividend Growth Stocks to Buy For a Lifetime of Passive Income
Investing in dividend growth stocks is a smart, reliable way to build passive income that lasts a lifetime, and it's worth considering if you're eyeing financial freedom.
McKesson (MCK) Increases Yet Falls Behind Market: What Investors Need to Know
In the latest trading session, McKesson (MCK) closed at $663.79, marking a +0.33% move from the previous day.
McKesson (MCK) Advances While Market Declines: Some Information for Investors
McKesson (MCK) closed at $643.69 in the latest trading session, marking a +0.47% move from the prior day.
3 Stocks to Consider With a Possible Recession on the Table
As of early March 2025, investors—and consumers—have once again begun to feel skittish about the possibility of an impending recession. At least two major factors have contributed most recently to this sentiment: first, a dreaded inverted yield curve in the final days of February, and second, the Atlanta Fed's model to predict GDP growth for the first quarter of the year was revised down to -2.8% on March 3, when it had been +4.0% about a month before.
McKesson Keeps Growing, Eyeing Bigger Future
Health care product distributor McKesson Corporation (MCK) reports big earnings gains, eye care acquisition.
McKesson Corporation (MCK) TD Cowen 45th Annual Healthcare Conference Transcript
McKesson Corporation (NYSE:MCK ) TD Cowen 45th Annual Healthcare Conference Call March 4, 2025 9:50 AM ET Company Participants Britt Vitalone – Executive Vice President and Chief Financial Officer Conference Call Participants Unidentified Analyst Good morning. Thanks for joining us for the next session here at the TD Cowen Healthcare Conference and very pleased to have with us McKesson.
Is Most-Watched Stock McKesson Corporation (MCK) Worth Betting on Now?
Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Should You Buy, Hold or Sell MCK Stock Following Robust Q3 Earnings?
McKesson MCK delivered an 18% increase in revenues ($95.3 billion) and a 16% rise in adjusted operating profit during the third quarter of fiscal 2025 despite ongoing macroeconomic challenges. The company also raised its full-year guidance.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
MCK Stock Down on Q3 Earnings & Sales Miss, Gross Margin Contracts
McKesson's third-quarter fiscal 2025 results showcase growth in the U.S. Pharmaceutical segment. However, Medical Surgical Solutions suffers due to lower COVID-related sales.
